Optical Engine Manufacturing Operational at Globetronics in Malaysia and POET Technologies Snd. Bhd. Established as Wholly Owned SubsidiaryTORONTO, May 13, 2025 (GLOBE NEWSWIRE) -- POET Technologies Inc. ("POET" or the "Company") (TSX Venture: PTK; NASDAQ: POET), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks, today announced the appointment of Ghazi M. Chaoui, PhD, MBA as its Senior Vice President of Global Manufacturing ...

Management Delivers Impressive 80% Revenue Growth Quarter-Over-Quarter Beats All Revenue and EPS Estimates By A Wide Margin Q1 2025 Revenue Exceeds Entire 2024 Annual Revenue Closed $8.5 Million Acquisition Of AI Social Commerce Technology Platform Lyvecom $5 Million Cash Added To Balance Sheet In Non-Dilutive, Non-Convertible, Preferred Stock Deal Zero Debt - Strong Cash Position – Expected To Fund Operations Into 2028 And Beyond Increased Growth Projected For Q2 2025 LAS VEGAS, May 13, 2025 (GLOBE NEWSWIR ...

Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors ...

Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association of Immunologists MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inf ...

Core Insights - Hudson Global, Inc. reported stronger financial results for Q1 2025 compared to Q1 2024, despite an uncertain overall talent environment due to macro conditions [3][8] - The company is optimistic about future growth, particularly in its Hudson RPO segment, which is expected to outperform peers [3] Financial Performance - Total revenue for Q1 2025 was $31.9 million, a decrease of 6% from Q1 2024, while adjusted net revenue increased slightly by 0.4% to $16.4 million [8] - The net loss for Q1 2025 was $1.8 million, or $0.59 per diluted share, an improvement from a net loss of $2.9 million, or $0.95 per diluted share, in Q1 2024 [8][20] - Adjusted EBITDA loss was $0.7 million, a decrease from an adjusted EBITDA loss of $1.5 million in the same period last year [8] Regional Highlights - **Americas**: Revenue increased by 15% to $6.9 million, with adjusted net revenue up 3% to $6.0 million. EBITDA loss improved to $0.1 million from $0.9 million in the previous year [4] - **Asia Pacific**: Revenue decreased by 7% to $19.1 million, while adjusted net revenue increased by 14% to $7.2 million. EBITDA improved to a profit of $0.3 million from a loss of $0.6 million [5] - **EMEA**: Revenue decreased by 7% to $5.9 million, with adjusted net revenue down 19% to $3.2 million. EBITDA loss was $0.6 million compared to a profit of $0.3 million in the previous year [6] Corporate Costs and Liquidity - Corporate costs for Q1 2025 were $0.9 million, down from $1.0 million in the prior year [9] - The company ended Q1 2025 with $17.2 million in cash, including $0.7 million in restricted cash, and used $0.8 million in cash flow from operations [10] Share Repurchase Program - Hudson Global has a $5 million share repurchase program, with $2.5 million spent in 2024 to buy back 154,084 shares, leaving $2.1 million remaining [11] NOL Carryforward - As of December 31, 2024, Hudson Global had $240 million of usable net operating losses (NOL) in the U.S., which the company considers a valuable asset for stockholders [12]

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t ...

SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company's proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion. This approval marks a significa ...

Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart DiseaseSOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society of Gene and Cell Therapy (ASGCT 2025) 28th Ann ...

Range Truck Group joins as key Pacific Northwest partner; third Midwest Ziegler Truck Group location addedCINCINNATI, May 13, 2025 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today announced the expansion of its partnership with Ziegler Truck Group, adding two new dealer locations to its national network. Range Truck Group, located in Fife, Washington, joins t ...

Core Insights - Adial Pharmaceuticals has achieved a milestone by receiving a six-figure payment from Adovate, LLC, following the initiation of a Phase 1 clinical trial for ADO-5030, a novel asthma therapy targeting a significant market with unmet medical needs [1][2][3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders, with its lead product AD04 targeting Alcohol Use Disorder (AUD) [4] Financial Aspects - Under the agreement with Adovate, Adial is eligible for over $50 million in commercial milestone payments and an additional $11 million in development and approval milestone payments per compound, totaling up to $83 million for the first three compounds if milestones are achieved [3][7] - Adial retains a significant equity stake of over 10% in Adovate, allowing participation in the long-term upside as the asthma candidate progresses [3][7] Clinical Development - The ongoing Phase 1 study for ADO-5030 is a Single Ascending Dose (SAD) trial aimed at evaluating safety, tolerability, and pharmacokinetics in healthy volunteers, with the potential to shift the treatment paradigm for asthma patients globally [2][3]